With news yesterday out of the UK that the inexpensive and widely available steroid dexamethasone significantly reduced deaths in coronavirus patients who are intubated and those requiring oxygen, following published evidence last month that the antiviral Remdesivir shortened time to recovery, the search for a breakthrough drug or approach that improves survival before approval of a viable vaccine remains illusive.
Add to this the potential for the virus to mutate—already with multiple strains— the search for a new approach would be ideal.
Now, researchers at UC San Diego have pioneered a novel pathway for treating infections using “nanosponges”—a technology that may hold promise for treating patients with SARS-CoV-2, the virus responsible for Covid-19… Continue reading.
Nanoparticles disguised as human platelets could greatly enhance the healing power of drug treatments for cardiovascular disease and systemic bacterial infections. These platelet-mimicking nanoparticles, developed by engineers at the University of California, San Diego, are capable of delivering drugs to targeted sites in the body — particularly injured blood vessels, as well as organs infected by harmful bacteria. Engineers demonstrated that by delivering the drugs just to the areas where the drugs were needed, these platelet copycats greatly increased the therapeutic effects of drugs that were administered to diseased rats and mice.
The research, led by nanoengineers at the UC San Diego Jacobs School of Engineering, was published online Sept. 16 in Nature.
“This work addresses a major challenge in the field of nanomedicine: targeted drug delivery with nanoparticles,” said Liangfang Zhang, a nanoengineering professor at UC San Diego and the senior author of the study. “Because of their targeting ability, platelet-mimicking nanoparticles can directly provide a much higher dose of medication specifically to diseased areas without saturating the entire body with drugs.”
WASHINGTON, D.C.— The American Institute for Medical and Biological Engineering (AIMBE) has announced the pending induction of Liangfang Zhang, Ph.D., Professor, Department of Nanoengineering, University of California, San Diego, to its College of Fellows. Dr. Zhang was nominated, reviewed, and elected by peers and members of the College of Fellows For outstanding contributions to creating and advancing biomimetic nanomaterials for drug delivery to improve treatment of cancers and infectious diseases.